Leiden

• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• Phase 2 Study of ALXN2420 versus Placebo in Combination with Somatostatin Analogs in Participants with Acromegaly Halted
  2025-521243-20-00 4 2025-10-23 Acromegaly
• Methotrexate PK (in combination with Novobiocin) in RA patients Halted
  2025-522531-34-00 3 2025-08-19 Rheumatoid arthritis
• Research into the effects of the drug DMT in healthy volunteers Halted
  2025-521605-40-00 3 2025-06-10 major depressive disorder (MDD)
• PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy f … Halted
  2023-506194-35-00 5 2024-11-21 Colorectal liver metastases
• A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the … Halted
  2023-509451-14-00 7 2022-11-01 Metastatic uveal melanoma
• A study to evaluate the safety and effectiveness of a new gene therapy (XC001) for people with coronary artery disease and reduced heart fun … Ended
  2025-521325-33-00 4 2026-03-18 Chronic angina and left ventricular dysfunction due to coronary artery
• The effect of SYX-5219 on an immune response in the skin. Ended
  2025-522217-27-00 3 2025-11-19 Atopic dermatitis (AD)
• Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone) Ended
  2025-522389-66-00 3 2025-09-24 (Chronic) pain
• A Study to Investigate the Effect of RO7504109 on Immune Cells in Healthy Participants Ended
  2025-522181-71-00 3 2025-09-17 Not Applicable (N/A)
• (IPCOM) Influence of Proton pump inhibitor CO-medication on the absorption of innovator and generic formulations of Mycophenolate mofetil Ended
  2024-517043-32-00 6 2025-07-08 Post Transplantation Patients
• A study to examine the effects of oral NTX-1955 on the brain in healthy adults. Ended
  2025-521829-32-00 3 2025-06-24 Generalized Anxiety Disorder (GAD)
• PainCart Study Evaluating the Analgesic Profile of SAGE-319 Ended
  2025-521380-12-00 3 2025-06-02 Disorders characterized by a deficit in GABAergic signaling and cerebe
• Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants Ended
  2024-512939-67-00 1 2025-05-10 Mental health disorders
• WOMEN&More: Efficacy, safety, and acceptability of mifepristone 50 mg once-weekly as a contraceptive Ended
  2022-502694-41-00 5 2025-04-14 Contraception
• Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema Ended
  2025-520514-64-00 1 2025-04-04 Atopic Dermatitis
• A study to compare the absorption of two tablet strengths with the absorption of a solution. Ended
  2024-519835-41-00 2 2025-02-28 Parkinson's Disease
• Measuring the macro- and microvascular responses to LPS and exenatide Ended
  2024-519014-31-00 3 2025-02-26 Cardiovascular and metabolic diseases
• A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ASCENDING, SINGLE-DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC … Ended
  2024-515151-38-00 3 2024-12-06 Nervous System disease
• TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents ag … Ended
  2024-515263-60-00 6 2024-11-22 SARS-CoV-2 infection
• Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization Ended
  2024-512651-20-00 4 2024-11-20 Fetal and Neonatal Alloimmune Thrombocytopenia due to Human Platelet A
• A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease. Ended
  2024-516888-84-00 3 2024-11-12 Parkinson's disease.
• Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, … Ended
  2024-513516-99-00 9 2024-10-28 Falciparum malaria
• THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE … Ended
  2024-516260-29-00 5 2024-10-10 non-metastatic (borderline) resectable pancreatic cancer

Showing 337–360 of 450 trials